 Kennon Heard
Concepts (647)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acetaminophen | 40 | 2025 | 246 | 8.800 |
Why?
| | Chemical and Drug Induced Liver Injury | 15 | 2023 | 132 | 4.860 |
Why?
| | Analgesics, Non-Narcotic | 21 | 2025 | 119 | 4.680 |
Why?
| | Drug Overdose | 31 | 2025 | 322 | 4.310 |
Why?
| | Emergency Service, Hospital | 41 | 2023 | 1901 | 3.580 |
Why?
| | Poison Control Centers | 13 | 2025 | 89 | 3.530 |
Why?
| | Poisoning | 17 | 2017 | 111 | 3.090 |
Why?
| | Alanine Transaminase | 14 | 2023 | 152 | 2.650 |
Why?
| | Acetylcysteine | 11 | 2023 | 146 | 2.640 |
Why?
| | Cocaine | 10 | 2011 | 148 | 2.490 |
Why?
| | Cannabis | 9 | 2020 | 463 | 2.420 |
Why?
| | Prescription Drugs | 9 | 2018 | 112 | 2.270 |
Why?
| | Analgesics, Opioid | 8 | 2023 | 913 | 1.600 |
Why?
| | Antidotes | 9 | 2020 | 136 | 1.550 |
Why?
| | Legislation, Drug | 5 | 2017 | 78 | 1.510 |
Why?
| | Cysteine | 4 | 2017 | 195 | 1.390 |
Why?
| | Antipsychotic Agents | 7 | 2019 | 194 | 1.360 |
Why?
| | Marijuana Use | 4 | 2021 | 192 | 1.250 |
Why?
| | Medication Errors | 5 | 2015 | 95 | 1.190 |
Why?
| | Male | 103 | 2022 | 63597 | 1.180 |
Why?
| | Humans | 155 | 2025 | 129385 | 1.140 |
Why?
| | Emergency Medicine | 6 | 2019 | 215 | 1.130 |
Why?
| | Cocaine-Related Disorders | 5 | 2011 | 108 | 1.120 |
Why?
| | Toxicology | 4 | 2021 | 41 | 1.080 |
Why?
| | Drug Packaging | 2 | 2017 | 41 | 1.080 |
Why?
| | Pain | 9 | 2020 | 785 | 1.080 |
Why?
| | Female | 95 | 2022 | 68693 | 1.020 |
Why?
| | Adult | 73 | 2022 | 35514 | 1.010 |
Why?
| | Medication Reconciliation | 2 | 2016 | 29 | 0.980 |
Why?
| | Dose-Response Relationship, Drug | 16 | 2017 | 2011 | 0.960 |
Why?
| | Antidepressive Agents, Tricyclic | 5 | 2014 | 30 | 0.910 |
Why?
| | Spider Bites | 5 | 2019 | 9 | 0.910 |
Why?
| | Antivenins | 5 | 2019 | 35 | 0.900 |
Why?
| | Diphenhydramine | 4 | 2023 | 31 | 0.900 |
Why?
| | Akathisia, Drug-Induced | 2 | 2020 | 6 | 0.880 |
Why?
| | Thiazoles | 4 | 2009 | 117 | 0.860 |
Why?
| | Benzodiazepines | 6 | 2023 | 135 | 0.850 |
Why?
| | Prescription Drug Monitoring Programs | 1 | 2023 | 14 | 0.850 |
Why?
| | Spider Venoms | 4 | 2019 | 11 | 0.840 |
Why?
| | Heart Arrest | 8 | 2018 | 321 | 0.820 |
Why?
| | Middle Aged | 54 | 2022 | 31102 | 0.810 |
Why?
| | Muscarinic Antagonists | 3 | 2023 | 27 | 0.810 |
Why?
| | Young Adult | 30 | 2020 | 12416 | 0.800 |
Why?
| | Lorazepam | 3 | 2023 | 26 | 0.800 |
Why?
| | Decision Support Systems, Clinical | 2 | 2023 | 205 | 0.780 |
Why?
| | Seizures | 6 | 2011 | 402 | 0.770 |
Why?
| | Referral and Consultation | 2 | 2020 | 731 | 0.770 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 337 | 0.750 |
Why?
| | Physostigmine | 2 | 2020 | 12 | 0.750 |
Why?
| | Emergency Treatment | 4 | 2015 | 113 | 0.750 |
Why?
| | Piperazines | 4 | 2009 | 342 | 0.750 |
Why?
| | Black Widow Spider | 4 | 2019 | 9 | 0.740 |
Why?
| | Delirium | 2 | 2020 | 78 | 0.730 |
Why?
| | Medical History Taking | 3 | 2018 | 118 | 0.730 |
Why?
| | Dopamine Uptake Inhibitors | 3 | 2011 | 55 | 0.730 |
Why?
| | Anti-Arrhythmia Agents | 4 | 2014 | 110 | 0.690 |
Why?
| | Suicide, Attempted | 5 | 2012 | 349 | 0.690 |
Why?
| | Abdominal Pain | 2 | 2019 | 144 | 0.690 |
Why?
| | Vasoconstrictor Agents | 4 | 2009 | 127 | 0.670 |
Why?
| | Retrospective Studies | 31 | 2023 | 14498 | 0.670 |
Why?
| | Hospitals, Pediatric | 4 | 2018 | 509 | 0.670 |
Why?
| | Emergency Medical Services | 5 | 2025 | 521 | 0.660 |
Why?
| | Back Pain | 1 | 2020 | 51 | 0.660 |
Why?
| | Free Radical Scavengers | 2 | 2011 | 83 | 0.650 |
Why?
| | Patient Handoff | 1 | 2020 | 31 | 0.650 |
Why?
| | Buprenorphine | 2 | 2020 | 162 | 0.640 |
Why?
| | Haloperidol | 1 | 2019 | 32 | 0.630 |
Why?
| | Ketorolac | 1 | 2019 | 21 | 0.630 |
Why?
| | Social Work | 1 | 2020 | 83 | 0.620 |
Why?
| | Pharmacoepidemiology | 1 | 2018 | 20 | 0.610 |
Why?
| | Gastric Lavage | 3 | 2009 | 9 | 0.590 |
Why?
| | Tertiary Care Centers | 3 | 2017 | 151 | 0.590 |
Why?
| | Colorado | 15 | 2021 | 4415 | 0.590 |
Why?
| | Prospective Studies | 18 | 2023 | 7111 | 0.590 |
Why?
| | Immunoglobulin Fab Fragments | 4 | 2019 | 59 | 0.590 |
Why?
| | Vomiting | 6 | 2019 | 126 | 0.590 |
Why?
| | Substance-Related Disorders | 5 | 2012 | 1022 | 0.580 |
Why?
| | Hypotension | 2 | 2022 | 116 | 0.570 |
Why?
| | Child | 28 | 2023 | 20868 | 0.570 |
Why?
| | Drug Storage | 2 | 2017 | 57 | 0.560 |
Why?
| | Electronic Health Records | 4 | 2024 | 975 | 0.550 |
Why?
| | Accidents, Home | 1 | 2017 | 29 | 0.550 |
Why?
| | Cannabinoids | 3 | 2017 | 153 | 0.550 |
Why?
| | Medical Marijuana | 2 | 2019 | 111 | 0.540 |
Why?
| | Pulmonary Embolism | 3 | 2021 | 211 | 0.540 |
Why?
| | Plant Preparations | 2 | 2015 | 32 | 0.540 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2007 | 82 | 0.540 |
Why?
| | Calcium Gluconate | 1 | 2016 | 4 | 0.530 |
Why?
| | Hypocalcemia | 1 | 2016 | 28 | 0.520 |
Why?
| | Quaternary Ammonium Compounds | 1 | 2016 | 53 | 0.520 |
Why?
| | Health Records, Personal | 1 | 2016 | 26 | 0.510 |
Why?
| | Mobile Applications | 1 | 2018 | 159 | 0.510 |
Why?
| | Nonprescription Drugs | 4 | 2016 | 66 | 0.500 |
Why?
| | Blood Proteins | 1 | 2017 | 242 | 0.500 |
Why?
| | Practice Patterns, Physicians' | 3 | 2023 | 1265 | 0.500 |
Why?
| | Antidepressive Agents | 2 | 2012 | 228 | 0.490 |
Why?
| | Fat Emulsions, Intravenous | 2 | 2014 | 28 | 0.490 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 5 | 2023 | 253 | 0.490 |
Why?
| | Prescription Drug Misuse | 1 | 2015 | 39 | 0.480 |
Why?
| | Liver | 6 | 2022 | 1839 | 0.480 |
Why?
| | Treatment Outcome | 18 | 2020 | 10195 | 0.480 |
Why?
| | Electrocardiography | 5 | 2013 | 606 | 0.470 |
Why?
| | Child, Preschool | 13 | 2018 | 10516 | 0.460 |
Why?
| | Infant | 12 | 2018 | 9023 | 0.450 |
Why?
| | Asymptomatic Diseases | 2 | 2013 | 84 | 0.440 |
Why?
| | Crime | 2 | 2011 | 57 | 0.440 |
Why?
| | Observer Variation | 3 | 2010 | 314 | 0.440 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 1 | 2013 | 24 | 0.430 |
Why?
| | Energy Drinks | 1 | 2013 | 4 | 0.430 |
Why?
| | Adolescent | 27 | 2020 | 20378 | 0.430 |
Why?
| | Performance-Enhancing Substances | 1 | 2013 | 9 | 0.420 |
Why?
| | Arrhythmias, Cardiac | 3 | 2022 | 315 | 0.420 |
Why?
| | Double-Blind Method | 7 | 2020 | 1876 | 0.420 |
Why?
| | Accidents | 1 | 2013 | 39 | 0.420 |
Why?
| | Bradycardia | 1 | 2013 | 53 | 0.420 |
Why?
| | Poisons | 2 | 2023 | 20 | 0.410 |
Why?
| | Plasmapheresis | 1 | 2013 | 23 | 0.410 |
Why?
| | Diet Surveys | 1 | 2013 | 92 | 0.410 |
Why?
| | Amphotericin B | 1 | 2013 | 29 | 0.410 |
Why?
| | Hematemesis | 1 | 2012 | 3 | 0.410 |
Why?
| | beta-Alanine | 1 | 2012 | 16 | 0.410 |
Why?
| | Phytotherapy | 1 | 2013 | 79 | 0.410 |
Why?
| | Foreign Bodies | 2 | 2011 | 101 | 0.410 |
Why?
| | Aspartate Aminotransferases | 3 | 2010 | 87 | 0.410 |
Why?
| | Stomach Diseases | 1 | 2012 | 20 | 0.410 |
Why?
| | Ethers | 1 | 2012 | 16 | 0.400 |
Why?
| | Sulfonylurea Compounds | 2 | 2010 | 46 | 0.400 |
Why?
| | Citalopram | 1 | 2012 | 30 | 0.390 |
Why?
| | Aged | 27 | 2019 | 22052 | 0.390 |
Why?
| | Antithrombins | 1 | 2012 | 58 | 0.390 |
Why?
| | Liver Function Tests | 7 | 2020 | 112 | 0.390 |
Why?
| | Antifungal Agents | 1 | 2013 | 129 | 0.390 |
Why?
| | Drug Administration Schedule | 5 | 2014 | 768 | 0.390 |
Why?
| | Dronabinol | 4 | 2021 | 203 | 0.390 |
Why?
| | Propafenone | 1 | 2011 | 2 | 0.380 |
Why?
| | Genetic Predisposition to Disease | 1 | 2020 | 2281 | 0.380 |
Why?
| | Thiophenes | 1 | 2012 | 118 | 0.380 |
Why?
| | Disease Models, Animal | 9 | 2011 | 4063 | 0.380 |
Why?
| | C-Peptide | 2 | 2010 | 163 | 0.380 |
Why?
| | Alcohol Drinking | 4 | 2012 | 764 | 0.380 |
Why?
| | Opioid-Related Disorders | 2 | 2020 | 484 | 0.380 |
Why?
| | Firesetting Behavior | 1 | 2011 | 1 | 0.370 |
Why?
| | Anaphylaxis | 2 | 2012 | 98 | 0.370 |
Why?
| | Infusions, Intravenous | 6 | 2013 | 398 | 0.370 |
Why?
| | Clinical Enzyme Tests | 2 | 2013 | 10 | 0.370 |
Why?
| | Charcoal | 4 | 2006 | 24 | 0.370 |
Why?
| | Benzimidazoles | 1 | 2012 | 162 | 0.370 |
Why?
| | Temperance | 2 | 2010 | 13 | 0.370 |
Why?
| | Administration, Intravenous | 4 | 2016 | 139 | 0.360 |
Why?
| | Aged, 80 and over | 15 | 2018 | 7069 | 0.360 |
Why?
| | Burns | 2 | 2015 | 286 | 0.360 |
Why?
| | Chemical and Drug Induced Liver Injury, Chronic | 1 | 2011 | 11 | 0.360 |
Why?
| | Brain Edema | 1 | 2011 | 60 | 0.360 |
Why?
| | Reproducibility of Results | 6 | 2024 | 3079 | 0.360 |
Why?
| | Amitriptyline | 2 | 2001 | 19 | 0.350 |
Why?
| | Cholinergic Antagonists | 1 | 2011 | 29 | 0.350 |
Why?
| | Evidence-Based Medicine | 4 | 2023 | 715 | 0.350 |
Why?
| | Self-Injurious Behavior | 1 | 2012 | 120 | 0.350 |
Why?
| | Blood Chemical Analysis | 3 | 2021 | 95 | 0.350 |
Why?
| | Immunologic Factors | 2 | 2019 | 231 | 0.350 |
Why?
| | Tachycardia, Ventricular | 1 | 2012 | 167 | 0.350 |
Why?
| | Population Surveillance | 1 | 2013 | 436 | 0.340 |
Why?
| | Liver Failure | 1 | 2011 | 91 | 0.340 |
Why?
| | Hydrofluoric Acid | 2 | 2016 | 8 | 0.340 |
Why?
| | Time Factors | 12 | 2020 | 6550 | 0.340 |
Why?
| | United States | 18 | 2025 | 13876 | 0.340 |
Why?
| | Pharmaceutical Vehicles | 1 | 2010 | 11 | 0.340 |
Why?
| | Propylene Glycol | 1 | 2010 | 10 | 0.340 |
Why?
| | Barium | 1 | 2009 | 28 | 0.330 |
Why?
| | Explosive Agents | 1 | 2009 | 6 | 0.330 |
Why?
| | Hypokalemia | 1 | 2009 | 24 | 0.330 |
Why?
| | Imines | 2 | 2022 | 8 | 0.330 |
Why?
| | Warfarin | 1 | 2010 | 147 | 0.330 |
Why?
| | Liver Diseases, Alcoholic | 2 | 2007 | 89 | 0.330 |
Why?
| | Iatrogenic Disease | 1 | 2010 | 54 | 0.330 |
Why?
| | Cross-Sectional Studies | 9 | 2020 | 5061 | 0.330 |
Why?
| | Acidosis, Lactic | 1 | 2010 | 46 | 0.320 |
Why?
| | Emetics | 2 | 2006 | 7 | 0.320 |
Why?
| | Deception | 1 | 2009 | 18 | 0.320 |
Why?
| | Random Allocation | 3 | 2007 | 346 | 0.320 |
Why?
| | Surveys and Questionnaires | 4 | 2018 | 5390 | 0.320 |
Why?
| | Benzoquinones | 2 | 2022 | 48 | 0.320 |
Why?
| | Risk Factors | 9 | 2017 | 9752 | 0.310 |
Why?
| | Risk Assessment | 8 | 2017 | 3236 | 0.310 |
Why?
| | Oximetry | 1 | 2009 | 87 | 0.310 |
Why?
| | Length of Stay | 3 | 2020 | 1124 | 0.310 |
Why?
| | Fluorides | 2 | 2016 | 50 | 0.310 |
Why?
| | Odds Ratio | 7 | 2017 | 1023 | 0.310 |
Why?
| | Hypothermia, Induced | 1 | 2009 | 76 | 0.300 |
Why?
| | Point-of-Care Systems | 1 | 2010 | 146 | 0.300 |
Why?
| | Cyanoacrylates | 1 | 2008 | 4 | 0.290 |
Why?
| | Eyelashes | 1 | 2008 | 4 | 0.290 |
Why?
| | Intellectual Disability | 1 | 2009 | 149 | 0.290 |
Why?
| | Hypoglycemia | 2 | 2010 | 426 | 0.290 |
Why?
| | Adhesives | 1 | 2008 | 13 | 0.290 |
Why?
| | Alcoholism | 4 | 2023 | 766 | 0.290 |
Why?
| | Reference Values | 4 | 2017 | 793 | 0.290 |
Why?
| | Detergents | 1 | 2008 | 45 | 0.290 |
Why?
| | Animals | 22 | 2019 | 35351 | 0.290 |
Why?
| | Cardiovascular System | 1 | 2009 | 137 | 0.280 |
Why?
| | Publishing | 1 | 2009 | 140 | 0.280 |
Why?
| | Brugada Syndrome | 1 | 2007 | 9 | 0.280 |
Why?
| | Polyethylene Glycols | 1 | 2012 | 601 | 0.280 |
Why?
| | Niacin | 1 | 2007 | 19 | 0.280 |
Why?
| | Diazepam | 1 | 2007 | 34 | 0.280 |
Why?
| | Clinical Laboratory Techniques | 1 | 2008 | 94 | 0.280 |
Why?
| | Mice, Inbred Strains | 4 | 2009 | 406 | 0.270 |
Why?
| | Vitamin B Complex | 1 | 2007 | 41 | 0.270 |
Why?
| | Pediatrics | 1 | 2015 | 1052 | 0.270 |
Why?
| | Specimen Handling | 1 | 2008 | 163 | 0.270 |
Why?
| | Thromboembolism | 1 | 2007 | 112 | 0.260 |
Why?
| | Brain Infarction | 1 | 2006 | 23 | 0.260 |
Why?
| | Analgesics | 4 | 2017 | 186 | 0.260 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2006 | 34 | 0.250 |
Why?
| | Decontamination | 1 | 2006 | 24 | 0.250 |
Why?
| | Nausea | 4 | 2014 | 108 | 0.250 |
Why?
| | Anticoagulants | 1 | 2010 | 636 | 0.250 |
Why?
| | Amiodarone | 1 | 2005 | 24 | 0.250 |
Why?
| | Self Report | 4 | 2021 | 799 | 0.250 |
Why?
| | Age Factors | 7 | 2017 | 3144 | 0.250 |
Why?
| | Intention | 1 | 2007 | 162 | 0.250 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2012 | 1360 | 0.250 |
Why?
| | Venous Thrombosis | 1 | 2007 | 176 | 0.250 |
Why?
| | Epilepsy | 2 | 2020 | 329 | 0.240 |
Why?
| | Vasospasm, Intracranial | 1 | 2005 | 17 | 0.240 |
Why?
| | Eating | 4 | 2017 | 369 | 0.240 |
Why?
| | Databases, Factual | 1 | 2010 | 1269 | 0.240 |
Why?
| | Sodium Nitrite | 1 | 2005 | 39 | 0.240 |
Why?
| | Drug Utilization | 5 | 2014 | 169 | 0.240 |
Why?
| | Education, Medical | 2 | 2021 | 243 | 0.240 |
Why?
| | Subarachnoid Hemorrhage | 1 | 2005 | 63 | 0.230 |
Why?
| | Calcium | 3 | 2016 | 1209 | 0.230 |
Why?
| | Acute Kidney Injury | 1 | 2012 | 790 | 0.230 |
Why?
| | Diagnostic Imaging | 1 | 2007 | 334 | 0.230 |
Why?
| | Coma | 2 | 2006 | 32 | 0.230 |
Why?
| | Biomarkers | 7 | 2021 | 3972 | 0.220 |
Why?
| | Triage | 2 | 2025 | 205 | 0.220 |
Why?
| | Hypoglycemic Agents | 2 | 2010 | 1219 | 0.220 |
Why?
| | Hospitals, Urban | 5 | 2021 | 129 | 0.220 |
Why?
| | Injections, Intraperitoneal | 4 | 2009 | 111 | 0.220 |
Why?
| | Case-Control Studies | 4 | 2022 | 3375 | 0.210 |
Why?
| | Insulin | 3 | 2019 | 2325 | 0.210 |
Why?
| | Anti-Anxiety Agents | 2 | 2020 | 45 | 0.210 |
Why?
| | Animal Experimentation | 1 | 2003 | 6 | 0.210 |
Why?
| | Glasgow Coma Scale | 1 | 2004 | 167 | 0.210 |
Why?
| | Sensitivity and Specificity | 5 | 2010 | 1835 | 0.210 |
Why?
| | Fibrinolytic Agents | 2 | 2021 | 263 | 0.210 |
Why?
| | Calcium Chloride | 1 | 2003 | 13 | 0.210 |
Why?
| | Hospitals, Teaching | 3 | 2014 | 113 | 0.200 |
Why?
| | Magnesium Sulfate | 1 | 2003 | 18 | 0.200 |
Why?
| | Cardiopulmonary Resuscitation | 3 | 2018 | 232 | 0.200 |
Why?
| | Longevity | 3 | 2009 | 151 | 0.200 |
Why?
| | Documentation | 1 | 2024 | 183 | 0.200 |
Why?
| | Umbilical Cord | 2 | 2021 | 83 | 0.190 |
Why?
| | Placebos | 2 | 2014 | 201 | 0.190 |
Why?
| | Desipramine | 1 | 2001 | 10 | 0.190 |
Why?
| | Phenylurea Compounds | 1 | 2022 | 89 | 0.190 |
Why?
| | Logistic Models | 3 | 2017 | 1986 | 0.190 |
Why?
| | Confidence Intervals | 4 | 2010 | 317 | 0.190 |
Why?
| | Research Design | 3 | 2006 | 1038 | 0.190 |
Why?
| | Opiate Substitution Treatment | 2 | 2020 | 136 | 0.180 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2023 | 176 | 0.180 |
Why?
| | Narcotic Antagonists | 2 | 2020 | 164 | 0.180 |
Why?
| | Severity of Illness Index | 1 | 2009 | 2737 | 0.180 |
Why?
| | Sinus Thrombosis, Intracranial | 1 | 2021 | 20 | 0.180 |
Why?
| | Hyperthermia, Induced | 1 | 2022 | 109 | 0.180 |
Why?
| | Heart Atria | 1 | 2001 | 128 | 0.180 |
Why?
| | Fractures, Bone | 2 | 2017 | 392 | 0.180 |
Why?
| | Acute Disease | 2 | 2019 | 978 | 0.170 |
Why?
| | Myocardial Contraction | 1 | 2001 | 335 | 0.170 |
Why?
| | Immunoglobulin Fragments | 1 | 1999 | 11 | 0.170 |
Why?
| | Lysergic Acid Diethylamide | 1 | 1999 | 2 | 0.170 |
Why?
| | Droperidol | 1 | 1999 | 4 | 0.160 |
Why?
| | Wisconsin | 1 | 2020 | 99 | 0.160 |
Why?
| | Lithium Carbonate | 1 | 1999 | 5 | 0.160 |
Why?
| | Serotonin Syndrome | 1 | 1999 | 5 | 0.160 |
Why?
| | Survival Analysis | 4 | 2010 | 1272 | 0.160 |
Why?
| | Starch | 1 | 2019 | 22 | 0.160 |
Why?
| | Serotonin Receptor Agonists | 1 | 1999 | 28 | 0.160 |
Why?
| | Scorpion Stings | 1 | 1999 | 1 | 0.160 |
Why?
| | Nutritive Value | 1 | 2019 | 36 | 0.160 |
Why?
| | Geriatric Assessment | 2 | 2011 | 205 | 0.160 |
Why?
| | Community Health Workers | 1 | 2020 | 55 | 0.160 |
Why?
| | Healthy Volunteers | 2 | 2019 | 199 | 0.160 |
Why?
| | Administration, Oral | 4 | 2019 | 785 | 0.160 |
Why?
| | Ventricular Premature Complexes | 1 | 1999 | 36 | 0.160 |
Why?
| | Thrombocytopenia | 1 | 2021 | 186 | 0.160 |
Why?
| | Snake Bites | 1 | 1999 | 28 | 0.160 |
Why?
| | Mass Screening | 1 | 2007 | 1148 | 0.160 |
Why?
| | Immune System | 1 | 2020 | 175 | 0.160 |
Why?
| | Fallopian Tube Diseases | 1 | 1998 | 5 | 0.160 |
Why?
| | Pregnancy, Tubal | 1 | 1998 | 5 | 0.160 |
Why?
| | Metabolome | 1 | 2022 | 338 | 0.160 |
Why?
| | Munchausen Syndrome by Proxy | 1 | 1998 | 2 | 0.150 |
Why?
| | Dietary Carbohydrates | 1 | 2019 | 150 | 0.150 |
Why?
| | Abortifacient Agents, Nonsteroidal | 1 | 1998 | 21 | 0.150 |
Why?
| | Cohort Studies | 7 | 2023 | 5414 | 0.150 |
Why?
| | Drug Therapy, Combination | 4 | 2011 | 1039 | 0.150 |
Why?
| | Cannabidiol | 1 | 2020 | 108 | 0.150 |
Why?
| | Plant Extracts | 1 | 2020 | 199 | 0.150 |
Why?
| | Anticonvulsants | 1 | 2020 | 209 | 0.150 |
Why?
| | Chi-Square Distribution | 2 | 2017 | 515 | 0.150 |
Why?
| | Sex Factors | 5 | 2022 | 1966 | 0.150 |
Why?
| | Sulfasalazine | 1 | 1998 | 23 | 0.150 |
Why?
| | Drug Antagonism | 2 | 2009 | 10 | 0.150 |
Why?
| | Out-of-Hospital Cardiac Arrest | 1 | 2018 | 70 | 0.140 |
Why?
| | Faculty, Medical | 1 | 2021 | 264 | 0.140 |
Why?
| | Dietary Fats | 1 | 2019 | 301 | 0.140 |
Why?
| | Genome-Wide Association Study | 2 | 2023 | 1332 | 0.140 |
Why?
| | Dyspnea | 1 | 1999 | 241 | 0.140 |
Why?
| | Drug Interactions | 4 | 2014 | 394 | 0.140 |
Why?
| | Fellowships and Scholarships | 1 | 2021 | 273 | 0.140 |
Why?
| | Gastrointestinal Agents | 1 | 1998 | 61 | 0.140 |
Why?
| | Methotrexate | 1 | 1998 | 249 | 0.140 |
Why?
| | Mice | 8 | 2009 | 16937 | 0.140 |
Why?
| | Continuity of Patient Care | 1 | 2020 | 275 | 0.140 |
Why?
| | Simulation Training | 1 | 2018 | 82 | 0.140 |
Why?
| | Survival Rate | 3 | 2013 | 1874 | 0.140 |
Why?
| | Incidence | 4 | 2013 | 2641 | 0.140 |
Why?
| | Peptide Fragments | 1 | 2021 | 692 | 0.140 |
Why?
| | Ammonium Compounds | 1 | 2016 | 3 | 0.130 |
Why?
| | Hypnotics and Sedatives | 1 | 1998 | 174 | 0.130 |
Why?
| | Energy Intake | 1 | 2019 | 461 | 0.130 |
Why?
| | Pain Management | 2 | 2017 | 325 | 0.130 |
Why?
| | Clinical Trials as Topic | 2 | 2012 | 1004 | 0.130 |
Why?
| | Prenatal Care | 1 | 2019 | 276 | 0.130 |
Why?
| | Cytochrome P-450 CYP2E1 Inhibitors | 1 | 2016 | 2 | 0.130 |
Why?
| | Metabolic Clearance Rate | 2 | 2019 | 118 | 0.130 |
Why?
| | Ventricular Fibrillation | 1 | 2016 | 57 | 0.130 |
Why?
| | Half-Life | 2 | 2019 | 162 | 0.130 |
Why?
| | Predictive Value of Tests | 3 | 2015 | 1945 | 0.130 |
Why?
| | Pharmacovigilance | 1 | 2015 | 21 | 0.130 |
Why?
| | Milk | 1 | 2016 | 119 | 0.120 |
Why?
| | Herniorrhaphy | 1 | 2016 | 57 | 0.120 |
Why?
| | Genetic Variation | 1 | 2020 | 937 | 0.120 |
Why?
| | Pilot Projects | 1 | 2020 | 1587 | 0.120 |
Why?
| | Fatal Outcome | 2 | 2013 | 300 | 0.120 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2015 | 74 | 0.120 |
Why?
| | Models, Biological | 2 | 2015 | 1719 | 0.120 |
Why?
| | Hemodialysis Units, Hospital | 1 | 1994 | 5 | 0.120 |
Why?
| | Child Behavior | 1 | 2017 | 235 | 0.120 |
Why?
| | Ondansetron | 1 | 2014 | 15 | 0.120 |
Why?
| | Liver Failure, Acute | 1 | 2015 | 64 | 0.120 |
Why?
| | Patient Simulation | 1 | 2014 | 33 | 0.120 |
Why?
| | Hydrocodone | 1 | 2014 | 16 | 0.110 |
Why?
| | Total Quality Management | 1 | 1994 | 60 | 0.110 |
Why?
| | Cytochrome P-450 CYP2D6 | 1 | 2014 | 29 | 0.110 |
Why?
| | Internship and Residency | 2 | 2014 | 1050 | 0.110 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2015 | 89 | 0.110 |
Why?
| | Curriculum | 1 | 2021 | 911 | 0.110 |
Why?
| | Transaminases | 1 | 2014 | 23 | 0.110 |
Why?
| | Oxycodone | 1 | 2014 | 43 | 0.110 |
Why?
| | Physicians | 2 | 2020 | 864 | 0.110 |
Why?
| | Guanfacine | 1 | 2013 | 4 | 0.110 |
Why?
| | Remote Consultation | 1 | 2014 | 47 | 0.110 |
Why?
| | Prognosis | 3 | 2011 | 3791 | 0.110 |
Why?
| | Pregnancy Complications | 1 | 2019 | 492 | 0.110 |
Why?
| | Clonidine | 1 | 2013 | 27 | 0.110 |
Why?
| | Vitamins | 1 | 2015 | 174 | 0.110 |
Why?
| | Acute Pain | 1 | 2014 | 45 | 0.110 |
Why?
| | International Normalized Ratio | 2 | 2011 | 46 | 0.110 |
Why?
| | Cesium | 1 | 2013 | 20 | 0.110 |
Why?
| | Indazoles | 1 | 2014 | 65 | 0.110 |
Why?
| | Food | 1 | 2015 | 157 | 0.110 |
Why?
| | Deoxycholic Acid | 1 | 2013 | 14 | 0.100 |
Why?
| | Canada | 2 | 2025 | 347 | 0.100 |
Why?
| | Walking | 1 | 2017 | 501 | 0.100 |
Why?
| | Lethargy | 1 | 2012 | 4 | 0.100 |
Why?
| | Duloxetine Hydrochloride | 1 | 2012 | 11 | 0.100 |
Why?
| | Dabigatran | 1 | 2012 | 21 | 0.100 |
Why?
| | Pain Measurement | 4 | 2019 | 502 | 0.100 |
Why?
| | Attitude of Health Personnel | 1 | 2020 | 1093 | 0.100 |
Why?
| | Sleep Stages | 1 | 2012 | 45 | 0.100 |
Why?
| | Tachycardia | 1 | 2012 | 57 | 0.100 |
Why?
| | Pyrazoles | 1 | 2016 | 405 | 0.100 |
Why?
| | Chlorides | 1 | 2013 | 139 | 0.100 |
Why?
| | Mycoses | 1 | 2013 | 70 | 0.100 |
Why?
| | Sulfhydryl Reagents | 1 | 2012 | 12 | 0.100 |
Why?
| | Data Collection | 2 | 2013 | 649 | 0.100 |
Why?
| | Marijuana Abuse | 1 | 2015 | 233 | 0.100 |
Why?
| | Dizziness | 1 | 2012 | 80 | 0.100 |
Why?
| | Athletic Performance | 1 | 2013 | 76 | 0.100 |
Why?
| | Sampling Studies | 1 | 2012 | 96 | 0.100 |
Why?
| | Accidental Falls | 2 | 2011 | 169 | 0.100 |
Why?
| | Magnesium | 2 | 2004 | 152 | 0.100 |
Why?
| | Patient Discharge | 2 | 2016 | 855 | 0.100 |
Why?
| | Arsenicals | 1 | 2012 | 32 | 0.100 |
Why?
| | Drug Combinations | 1 | 2013 | 329 | 0.090 |
Why?
| | Information Systems | 1 | 2011 | 61 | 0.090 |
Why?
| | Follow-Up Studies | 3 | 2010 | 4888 | 0.090 |
Why?
| | Sulfides | 1 | 2012 | 94 | 0.090 |
Why?
| | Marijuana Smoking | 1 | 2015 | 247 | 0.090 |
Why?
| | Laparoscopy | 1 | 2016 | 451 | 0.090 |
Why?
| | Arabia | 1 | 2011 | 2 | 0.090 |
Why?
| | Levamisole | 1 | 2011 | 19 | 0.090 |
Why?
| | Hepatic Encephalopathy | 1 | 2011 | 19 | 0.090 |
Why?
| | Immunocompromised Host | 1 | 2013 | 197 | 0.090 |
Why?
| | Structure-Activity Relationship | 1 | 2012 | 548 | 0.090 |
Why?
| | Drug Contamination | 1 | 2011 | 51 | 0.090 |
Why?
| | Molecular Structure | 1 | 2012 | 481 | 0.090 |
Why?
| | Dietary Supplements | 1 | 2015 | 533 | 0.090 |
Why?
| | Universities | 1 | 2013 | 405 | 0.090 |
Why?
| | Pharmacogenetics | 1 | 2012 | 175 | 0.090 |
Why?
| | Glipizide | 1 | 2010 | 6 | 0.090 |
Why?
| | Laboratories, Hospital | 1 | 2010 | 14 | 0.090 |
Why?
| | Sports | 1 | 2013 | 225 | 0.090 |
Why?
| | Hepatitis, Alcoholic | 1 | 2010 | 13 | 0.090 |
Why?
| | Troponin | 1 | 2010 | 50 | 0.080 |
Why?
| | Glyburide | 1 | 2010 | 35 | 0.080 |
Why?
| | Crowding | 1 | 2010 | 35 | 0.080 |
Why?
| | Drug Prescriptions | 2 | 2016 | 248 | 0.080 |
Why?
| | Watchful Waiting | 1 | 2010 | 66 | 0.080 |
Why?
| | Biological Availability | 2 | 2019 | 147 | 0.080 |
Why?
| | Adjuvants, Immunologic | 1 | 2011 | 221 | 0.080 |
Why?
| | Body Weight | 1 | 2014 | 940 | 0.080 |
Why?
| | Quetiapine Fumarate | 1 | 2009 | 22 | 0.080 |
Why?
| | Dibenzothiazepines | 1 | 2009 | 17 | 0.080 |
Why?
| | Aripiprazole | 1 | 2009 | 16 | 0.080 |
Why?
| | Risperidone | 1 | 2009 | 29 | 0.080 |
Why?
| | Potassium | 1 | 2009 | 143 | 0.080 |
Why?
| | Dogs | 1 | 2010 | 381 | 0.080 |
Why?
| | Efficiency, Organizational | 1 | 2010 | 133 | 0.080 |
Why?
| | Role | 1 | 2009 | 32 | 0.080 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2011 | 203 | 0.080 |
Why?
| | Head Protective Devices | 1 | 2009 | 19 | 0.080 |
Why?
| | Quality Control | 1 | 2009 | 163 | 0.080 |
Why?
| | Acidosis | 2 | 2006 | 89 | 0.080 |
Why?
| | Renal Dialysis | 1 | 2013 | 423 | 0.080 |
Why?
| | Body Temperature | 1 | 2009 | 212 | 0.080 |
Why?
| | Glutathione | 3 | 2022 | 348 | 0.080 |
Why?
| | Bibliometrics | 1 | 2009 | 53 | 0.080 |
Why?
| | Verapamil | 2 | 2014 | 41 | 0.080 |
Why?
| | Diarrhea | 1 | 2009 | 180 | 0.080 |
Why?
| | Workload | 1 | 2010 | 152 | 0.080 |
Why?
| | Quality Indicators, Health Care | 1 | 2011 | 296 | 0.080 |
Why?
| | Health Services Accessibility | 1 | 2015 | 902 | 0.070 |
Why?
| | Skiing | 1 | 2009 | 44 | 0.070 |
Why?
| | Informed Consent | 2 | 2006 | 168 | 0.070 |
Why?
| | Bacitracin | 1 | 2008 | 6 | 0.070 |
Why?
| | Adhesiveness | 1 | 2008 | 19 | 0.070 |
Why?
| | Acetone | 1 | 2008 | 12 | 0.070 |
Why?
| | Pharmacy Service, Hospital | 1 | 2009 | 90 | 0.070 |
Why?
| | Hair Preparations | 1 | 2008 | 7 | 0.070 |
Why?
| | Cause of Death | 1 | 2010 | 392 | 0.070 |
Why?
| | Propylene Glycols | 1 | 2008 | 27 | 0.070 |
Why?
| | Military Personnel | 1 | 2014 | 514 | 0.070 |
Why?
| | Nylons | 1 | 2008 | 20 | 0.070 |
Why?
| | Withholding Treatment | 1 | 2008 | 71 | 0.070 |
Why?
| | Students | 1 | 2013 | 576 | 0.070 |
Why?
| | Equipment Design | 1 | 2009 | 513 | 0.070 |
Why?
| | Glycerol | 1 | 2008 | 91 | 0.070 |
Why?
| | Cellulose | 1 | 2008 | 61 | 0.070 |
Why?
| | Quinolones | 1 | 2009 | 126 | 0.070 |
Why?
| | Substance Abuse Detection | 2 | 2021 | 79 | 0.070 |
Why?
| | Drug Synergism | 1 | 2008 | 371 | 0.070 |
Why?
| | Nephelometry and Turbidimetry | 1 | 2007 | 13 | 0.070 |
Why?
| | Polypharmacy | 1 | 2008 | 84 | 0.070 |
Why?
| | Laboratories | 1 | 2008 | 109 | 0.070 |
Why?
| | Tissue Distribution | 2 | 2019 | 315 | 0.070 |
Why?
| | Research | 2 | 2011 | 416 | 0.070 |
Why?
| | Phosphates | 1 | 2008 | 180 | 0.070 |
Why?
| | Formates | 1 | 2006 | 13 | 0.070 |
Why?
| | Defibrillators | 1 | 2006 | 16 | 0.070 |
Why?
| | Methanol | 1 | 2006 | 35 | 0.070 |
Why?
| | Combined Modality Therapy | 1 | 2009 | 1204 | 0.070 |
Why?
| | Periodicals as Topic | 1 | 2009 | 204 | 0.070 |
Why?
| | Kidney Transplantation | 1 | 2013 | 672 | 0.060 |
Why?
| | Hospitalization | 2 | 2011 | 2070 | 0.060 |
Why?
| | Blindness | 1 | 2006 | 38 | 0.060 |
Why?
| | Statistics, Nonparametric | 1 | 2007 | 422 | 0.060 |
Why?
| | Vasopressins | 1 | 2006 | 64 | 0.060 |
Why?
| | Aging | 2 | 2014 | 1776 | 0.060 |
Why?
| | Probability | 2 | 2010 | 306 | 0.060 |
Why?
| | Health Services for the Aged | 1 | 2006 | 72 | 0.060 |
Why?
| | Respiratory Insufficiency | 1 | 2009 | 313 | 0.060 |
Why?
| | Spinal Diseases | 1 | 2006 | 48 | 0.060 |
Why?
| | Epinephrine | 1 | 2006 | 141 | 0.060 |
Why?
| | Naproxen | 1 | 2006 | 17 | 0.060 |
Why?
| | Ipecac | 1 | 2005 | 8 | 0.060 |
Why?
| | Population Dynamics | 1 | 2006 | 138 | 0.060 |
Why?
| | Telemedicine | 1 | 2014 | 787 | 0.060 |
Why?
| | Haplorhini | 1 | 2005 | 50 | 0.060 |
Why?
| | Hospitals, University | 1 | 2006 | 178 | 0.060 |
Why?
| | Ibuprofen | 1 | 2006 | 81 | 0.060 |
Why?
| | Geriatrics | 1 | 2006 | 80 | 0.060 |
Why?
| | Premedication | 1 | 2005 | 42 | 0.060 |
Why?
| | Respiration, Artificial | 1 | 2009 | 609 | 0.060 |
Why?
| | Practice Guidelines as Topic | 2 | 2014 | 1494 | 0.060 |
Why?
| | Risk | 1 | 2007 | 854 | 0.060 |
Why?
| | Spine | 1 | 2006 | 158 | 0.060 |
Why?
| | Single-Blind Method | 1 | 2005 | 271 | 0.060 |
Why?
| | Water | 1 | 2008 | 446 | 0.060 |
Why?
| | Motivation | 1 | 2009 | 546 | 0.060 |
Why?
| | Fluoride Poisoning | 1 | 2004 | 3 | 0.060 |
Why?
| | Blood Glucose | 2 | 2019 | 2096 | 0.060 |
Why?
| | Resuscitation | 1 | 2006 | 237 | 0.060 |
Why?
| | Phenobarbital | 1 | 2023 | 19 | 0.060 |
Why?
| | Delphi Technique | 1 | 2025 | 222 | 0.050 |
Why?
| | Guidelines as Topic | 1 | 2005 | 263 | 0.050 |
Why?
| | Maltose | 1 | 2023 | 6 | 0.050 |
Why?
| | Hydroxyzine | 1 | 2023 | 3 | 0.050 |
Why?
| | Health Policy | 1 | 2006 | 353 | 0.050 |
Why?
| | Mycophenolic Acid | 1 | 2004 | 109 | 0.050 |
Why?
| | Sheep | 1 | 2006 | 837 | 0.050 |
Why?
| | Urea | 1 | 2023 | 77 | 0.050 |
Why?
| | Survival | 1 | 2003 | 39 | 0.050 |
Why?
| | Pregnancy | 3 | 2021 | 6397 | 0.050 |
Why?
| | Internet | 1 | 2007 | 615 | 0.050 |
Why?
| | Aspirin | 1 | 2006 | 380 | 0.050 |
Why?
| | Patient Participation | 1 | 2006 | 410 | 0.050 |
Why?
| | Lactates | 1 | 2022 | 85 | 0.050 |
Why?
| | Sex Distribution | 2 | 2015 | 359 | 0.050 |
Why?
| | Prevalence | 3 | 2015 | 2560 | 0.050 |
Why?
| | Urban Population | 2 | 2019 | 441 | 0.050 |
Why?
| | Culture Techniques | 1 | 2001 | 80 | 0.050 |
Why?
| | Consensus | 1 | 2025 | 613 | 0.050 |
Why?
| | Blood Physiological Phenomena | 1 | 2021 | 13 | 0.050 |
Why?
| | Neural Conduction | 1 | 2001 | 83 | 0.050 |
Why?
| | Academic Medical Centers | 2 | 2016 | 481 | 0.050 |
Why?
| | Hirudins | 1 | 2021 | 52 | 0.050 |
Why?
| | Breast Neoplasms | 1 | 2013 | 2142 | 0.040 |
Why?
| | Calcium Channel Blockers | 1 | 2001 | 161 | 0.040 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2020 | 27 | 0.040 |
Why?
| | Infusions, Parenteral | 1 | 2020 | 38 | 0.040 |
Why?
| | Certification | 1 | 2020 | 94 | 0.040 |
Why?
| | Pirenzepine | 1 | 1999 | 7 | 0.040 |
Why?
| | Scorpions | 1 | 1999 | 3 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2023 | 504 | 0.040 |
Why?
| | South America | 1 | 1999 | 58 | 0.040 |
Why?
| | Blood Cell Count | 2 | 2013 | 52 | 0.040 |
Why?
| | Narcotics | 1 | 1999 | 47 | 0.040 |
Why?
| | Temperature | 1 | 2022 | 634 | 0.040 |
Why?
| | Rupture, Spontaneous | 1 | 1998 | 18 | 0.040 |
Why?
| | Postprandial Period | 1 | 2019 | 104 | 0.040 |
Why?
| | Manikins | 1 | 2018 | 23 | 0.040 |
Why?
| | Central Nervous System Depressants | 1 | 1999 | 82 | 0.040 |
Why?
| | Videotape Recording | 1 | 2018 | 34 | 0.040 |
Why?
| | Sorption Detoxification | 1 | 1998 | 2 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2004 | 848 | 0.040 |
Why?
| | Analysis of Variance | 1 | 2001 | 1287 | 0.040 |
Why?
| | Dietary Proteins | 1 | 2019 | 128 | 0.040 |
Why?
| | Lipids | 1 | 2022 | 625 | 0.040 |
Why?
| | North America | 1 | 1999 | 291 | 0.040 |
Why?
| | Cholinesterase Inhibitors | 1 | 1998 | 29 | 0.040 |
Why?
| | Laparotomy | 1 | 1998 | 106 | 0.040 |
Why?
| | Feedback | 1 | 2018 | 162 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2021 | 1304 | 0.040 |
Why?
| | Cardiomyopathies | 1 | 2001 | 337 | 0.040 |
Why?
| | Central Nervous System | 1 | 1999 | 257 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2019 | 521 | 0.030 |
Why?
| | Maternal Health Services | 1 | 2019 | 95 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2001 | 845 | 0.030 |
Why?
| | Registries | 2 | 2010 | 1888 | 0.030 |
Why?
| | Triglycerides | 1 | 2019 | 527 | 0.030 |
Why?
| | Socioeconomic Factors | 2 | 2015 | 1214 | 0.030 |
Why?
| | Bipolar Disorder | 1 | 1999 | 235 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2019 | 1033 | 0.030 |
Why?
| | Hallucinogens | 1 | 2017 | 101 | 0.030 |
Why?
| | Dialysis | 1 | 2015 | 18 | 0.030 |
Why?
| | Centrifugation | 1 | 2015 | 30 | 0.030 |
Why?
| | Tennessee | 1 | 1994 | 43 | 0.030 |
Why?
| | Observation | 1 | 2014 | 51 | 0.030 |
Why?
| | Hematocrit | 1 | 1994 | 93 | 0.030 |
Why?
| | Anesthetics, Local | 1 | 2014 | 74 | 0.030 |
Why?
| | Syndrome | 1 | 2015 | 339 | 0.030 |
Why?
| | International Classification of Diseases | 1 | 2015 | 122 | 0.030 |
Why?
| | Program Evaluation | 1 | 2018 | 874 | 0.030 |
Why?
| | Warfare | 1 | 2014 | 63 | 0.030 |
Why?
| | Erythropoietin | 1 | 1994 | 86 | 0.030 |
Why?
| | Protein Binding | 1 | 2020 | 2121 | 0.030 |
Why?
| | Injections, Intralesional | 1 | 2013 | 34 | 0.030 |
Why?
| | Hospitals, Veterans | 1 | 1994 | 255 | 0.030 |
Why?
| | Salicylates | 1 | 2013 | 30 | 0.030 |
Why?
| | Urinalysis | 1 | 2013 | 74 | 0.030 |
Why?
| | Nursing Staff, Hospital | 1 | 1994 | 149 | 0.020 |
Why?
| | Iron | 1 | 1994 | 288 | 0.020 |
Why?
| | Hemoglobins | 1 | 1994 | 339 | 0.020 |
Why?
| | Long QT Syndrome | 1 | 2013 | 67 | 0.020 |
Why?
| | Therapeutic Irrigation | 1 | 2012 | 74 | 0.020 |
Why?
| | Receptors, Opioid, mu | 1 | 2012 | 65 | 0.020 |
Why?
| | Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2011 | 7 | 0.020 |
Why?
| | Agranulocytosis | 1 | 2011 | 30 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2011 | 53 | 0.020 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2012 | 151 | 0.020 |
Why?
| | Computer Simulation | 1 | 2015 | 943 | 0.020 |
Why?
| | Insulin Resistance | 1 | 2019 | 1165 | 0.020 |
Why?
| | Leukoencephalopathies | 1 | 2011 | 21 | 0.020 |
Why?
| | Fluid Therapy | 1 | 2012 | 134 | 0.020 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2011 | 128 | 0.020 |
Why?
| | Toothache | 1 | 2010 | 6 | 0.020 |
Why?
| | Models, Theoretical | 1 | 1994 | 545 | 0.020 |
Why?
| | Quality of Health Care | 1 | 2015 | 607 | 0.020 |
Why?
| | Disease Outbreaks | 1 | 2014 | 347 | 0.020 |
Why?
| | Immunoassay | 1 | 2011 | 107 | 0.020 |
Why?
| | Drug Administration Routes | 1 | 2010 | 38 | 0.020 |
Why?
| | Insurance Coverage | 1 | 2012 | 219 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2010 | 201 | 0.020 |
Why?
| | Neurologic Examination | 1 | 2010 | 115 | 0.020 |
Why?
| | Patient Education as Topic | 1 | 1994 | 738 | 0.020 |
Why?
| | Age Distribution | 1 | 2010 | 372 | 0.020 |
Why?
| | Intestines | 1 | 2012 | 347 | 0.020 |
Why?
| | Kidney Failure, Chronic | 1 | 1994 | 547 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2012 | 640 | 0.020 |
Why?
| | Safety | 1 | 2010 | 330 | 0.020 |
Why?
| | Precision Medicine | 1 | 2012 | 387 | 0.020 |
Why?
| | Ethanol | 1 | 2012 | 589 | 0.020 |
Why?
| | Regression Analysis | 1 | 2010 | 993 | 0.020 |
Why?
| | Seasons | 1 | 2010 | 501 | 0.020 |
Why?
| | Clinical Competence | 1 | 2014 | 1012 | 0.020 |
Why?
| | Disease Management | 1 | 2011 | 586 | 0.020 |
Why?
| | Bilirubin | 1 | 2007 | 96 | 0.020 |
Why?
| | Pulse | 1 | 2006 | 23 | 0.020 |
Why?
| | Genotype | 1 | 2012 | 1839 | 0.020 |
Why?
| | Metabolomics | 1 | 2012 | 652 | 0.020 |
Why?
| | Blastomycosis | 1 | 2006 | 10 | 0.020 |
Why?
| | Contraindications | 1 | 2006 | 90 | 0.020 |
Why?
| | Amyloidosis | 1 | 2006 | 40 | 0.020 |
Why?
| | Biopsy, Fine-Needle | 1 | 2006 | 66 | 0.020 |
Why?
| | Coronary Circulation | 1 | 2006 | 138 | 0.020 |
Why?
| | Electric Countershock | 1 | 2006 | 105 | 0.020 |
Why?
| | European Union | 1 | 2005 | 10 | 0.020 |
Why?
| | Fever | 1 | 2007 | 298 | 0.020 |
Why?
| | Disaster Planning | 1 | 2006 | 82 | 0.020 |
Why?
| | Infant, Newborn | 2 | 2007 | 5761 | 0.020 |
Why?
| | Emergencies | 1 | 2006 | 154 | 0.020 |
Why?
| | Administration, Inhalation | 1 | 2006 | 665 | 0.010 |
Why?
| | United States Food and Drug Administration | 1 | 2005 | 204 | 0.010 |
Why?
| | Up-Regulation | 1 | 2007 | 840 | 0.010 |
Why?
| | Renal Insufficiency | 1 | 2006 | 149 | 0.010 |
Why?
| | Pharmaceutical Preparations | 1 | 2006 | 171 | 0.010 |
Why?
| | Swine | 1 | 2006 | 760 | 0.010 |
Why?
| | Brain Injuries | 1 | 2009 | 468 | 0.010 |
Why?
| | Mice, Inbred ICR | 1 | 2004 | 110 | 0.010 |
Why?
| | Lupus Nephritis | 1 | 2004 | 49 | 0.010 |
Why?
| | Phenotype | 1 | 2012 | 3076 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2004 | 1083 | 0.010 |
Why?
| | Papillary Muscles | 1 | 2001 | 14 | 0.010 |
Why?
| | Models, Cardiovascular | 1 | 2001 | 191 | 0.010 |
Why?
| | Miosis | 1 | 1999 | 3 | 0.010 |
Why?
| | Pupil | 1 | 1999 | 13 | 0.010 |
Why?
| | Blood Pressure | 1 | 2006 | 1733 | 0.010 |
Why?
| | Hemodynamics | 1 | 2004 | 1086 | 0.010 |
Why?
| | Chronic Disease | 1 | 2004 | 1713 | 0.010 |
Why?
| | Algorithms | 1 | 2004 | 1620 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2001 | 2406 | 0.010 |
Why?
| | Rats | 1 | 2001 | 5497 | 0.010 |
Why?
| | Neoplasms | 1 | 2006 | 2469 | 0.010 |
Why?
|
|
Heard's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|